Andrew Allen, Gritstone bio CEO (via website)
September 27, 2023 04:01 PM EDTUpdated 04:49 PM
R&D

Grit­stone inks up to $433M con­tract with BAR­DA for 10,000-per­son Covid-19 vac­cine tri­al

Kyle LaHucik

Senior Reporter

Grit­stone bio will get up to $433 mil­lion from the US gov­ern­ment to run a Phase IIb tri­al ear­ly next year test­ing its self-am­pli­fy­ing mR­NA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times